2589-0409

Journal of the Egyptian National Cancer Institute

Springer (Biomed Central Ltd.)

View prefix report (10.1186)

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 179 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact179 DOIs
2

Add abstracts to 7 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact7 DOIs

DOIs for this ISSN

Showing the top 5 of 366 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Implications of photodynamic cancer therapy: an overview of… (10.1186/s43046-021-00093-1)
ORCID
47.16 76
2 Oct4 expression in gastric carcinoma: association with tumor… (10.1186/s43046-019-0005-0)
ORCID
41.80 46
3 Anticancer effects induced by artichoke extract in oral squa… (10.1186/s43046-020-00026-4)
ORCID
36.56 28
4 Selective cytotoxic effect of Plantago lanceolata L. against… (10.1186/s43046-019-0010-3)
Abstract
34.51 23
5 Drug delivery nanocarriers and recent advances ventured to i… (10.1186/s43046-021-00059-3)
ORCID
34.51 23
6 Pathologic assessment of tumor-associated macrophages and th… (10.1186/s43046-020-0018-8)
ORCID
34.04 22
7 Eco-biofabrication of silver nanoparticles from Azadirachta… (10.1186/s43046-024-00252-0)
ORCID
34.04 22
8 Subtyping of high grade serous ovarian carcinoma: histopatho… (10.1186/s43046-022-00104-9)
ORCID
32.53 19
9 Podophyllotoxin-polyacrylic acid conjugate micelles: improve… (10.1186/s43046-020-00053-1)
ORCID
31.97 18
10 Ligand-based drug design of quinazolin-4(3H)-ones as breast… (10.1186/s43046-023-00182-3)
ORCID
31.97 18
11 Advances in colorectal cancer screening and detection: a nar… (10.1186/s43046-025-00277-z)
ORCID
30.76 16
12 Unraveling exosome-mediated cancer therapy resistance: pathw… (10.1186/s43046-025-00289-9)
ORCID
30.76 16
13 Potential roles of claudin-3 and claudin-4 in ovarian cancer… (10.1186/s43046-022-00125-4)
ORCID
29.40 14
14 Studying ferroptosis and iron metabolism pre- and post-radio… (10.1186/s43046-023-00162-7)
ORCID
29.40 14
15 Dosimetric impact of variable bladder filling on IMRT planni… (10.1186/s43046-020-00033-5)
ORCID
27.85 12
16 Clinicopathological features and survival of colorectal canc… (10.1186/s43046-019-0006-z)
ORCID
26.98 11
17 Programmed death ligand-1 and CD8 tumor-infiltrating lymphoc… (10.1186/s43046-021-00073-5)
ORCID
26.98 11
18 Non-cancer to anti-cancer: investigation of human ether-a-go… (10.1186/s43046-021-00091-3)
ORCID
26.98 11
19 Mucinous cystadenocarcinoma of the breast: a new entity with… (10.1186/s43046-022-00112-9)
ORCID
26.98 11
20 Practical immunomodulatory landscape of glioblastoma multifo… (10.1186/s43046-024-00240-4)
ORCID
26.98 11
21 Immune-based cancer therapies: mechanistic insights, clinica… (10.1186/s43046-025-00319-6)
ORCID
26.98 11
22 Localized Wilms’ tumor in low-middle-income countries (LMIC)… (10.1186/s43046-020-00043-3)
ORCID
26.03 10
23 Prognostic significance of microRNA 17–92 cluster expression… (10.1186/s43046-021-00097-x)
ORCID
26.03 10
24 miR-155 and miR-92 levels in ALL, post-transplant aGVHD, and… (10.1186/s43046-023-00174-3)
ORCID
25.00 9
25 Metabolic syndrome and breast cancer risk (10.1186/s43046-023-00203-1)
ORCID
25.00 9
26 Green synthesis of copper nanoparticles: a promising solutio… (10.1186/s43046-024-00254-y)
ORCID
25.00 9
27 Integrative bioinformatics analysis reveals miR-494 and its… (10.1186/s43046-020-00028-2)
ORCID
23.86 8
28 Feasibility of Monte-Carlo algorithm in comparison with coll… (10.1186/s43046-020-00057-x)
ORCID
23.86 8
29 Detection of activating mutations in liquid biopsy of Egypti… (10.1186/s43046-021-00067-3)
ORCID
23.86 8
30 Prognostic factors and outcome of pineoblastoma: 10 years si… (10.1186/s43046-021-00083-3)
ORCID
23.86 8
31 The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins e… (10.1186/s43046-022-00121-8)
ORCID
23.86 8
32 Management and outcome of pediatric metastatic Wilms’ tumor… (10.1186/s43046-020-00031-7)
ORCID
22.58 7
33 Relapsed Wilms’ tumor in pediatric patients: challenges in l… (10.1186/s43046-020-00032-6)
ORCID
22.58 7
34 Demographics, clinical features, and prognosis of rare lymph… (10.1186/s43046-021-00103-2)
ORCID
22.58 7
35 A case report of carcinoma of uterine cervix throwing hetero… (10.1186/s43046-019-0009-9)
ORCID
21.13 6
36 Toll-like receptor 9 negatively related to clinical outcome… (10.1186/s43046-020-00027-3)
ORCID
21.13 6
37 Impact of DAXX and ATRX expression on telomere length and pr… (10.1186/s43046-020-00045-1)
ORCID
21.13 6
38 Combined effects of pioglitazone and doxorubicin on migratio… (10.1186/s43046-022-00110-x)
ORCID
21.13 6
39 Evaluation of molecular signatures in the urinary bladder an… (10.1186/s43046-022-00148-x)
ORCID
21.13 6
40 Role of tumor microenvironment in cancer promotion, developm… (10.1186/s43046-025-00317-8)
ORCID
21.13 6
41 Comparative study to evaluate dosimetric differences in pati… (10.1186/s43046-019-0003-2)
ORCID
19.45 5
42 A large helmet-shaped proliferating trichilemmal tumor of th… (10.1186/s43046-019-0007-y)
ORCID
19.45 5
43 The role of PI3K signaling pathway and its associated genes… (10.1186/s43046-021-00068-2)
ORCID
19.45 5
44 An in vitro cytotoxicity of glufosfamide in HepG2 cells rela… (10.1186/s43046-021-00080-6)
ORCID
19.45 5
45 Leptomeningeal carcinomatosis in a patient with recurrent un… (10.1186/s43046-022-00147-y)
ORCID
19.45 5
46 Stem cell therapy for hepatocellular carcinoma and end-stage… (10.1186/s43046-023-00194-z)
ORCID
19.45 5
47 Investigating the level of vitamin D receptor gene expressio… (10.1186/s43046-024-00215-5)
ORCID
19.45 5
48 The prevalence and clinical significance of EGFR mutations i… (10.1186/s43046-024-00251-1)
ORCID
19.45 5
49 Exploring potential additive effects of 5-fluorouracil, thym… (10.1186/s43046-025-00261-7)
ORCID
19.45 5
50 Atypical central neurocytoma with leptomeningeal disseminati… (10.1186/s43046-020-00030-8)
ORCID
17.47 4